Synthesis, characterization and antimicrobial properties of two derivatives of pyrrolidine-2,5-dione fused at positions-3,4 to a dibenzobarrelene backbone

Emmanuel Sopbué Fondjo1*, Abdou Salamou Njoya1, Jean-de-Dieu Tamokou2, Giscard Doungmo3, Bruno Ndjakou Lenta4, Peter F. W. Simon5, Apollinaire Tsopmo6 and Jules-Roger Kuiate2

Abstract
A new diazo derivative of a pyrrolidine-2,5-dione (8) fused at position-3,4 to a dibenzobarrelene backbone has been prepared by coupling the previously reported N-arylsuccinimid (5) precursor with aryldiazonium ion of aniline. The initial step of the reaction involved the preparation of the intermediate 9,10-dihydro-9,10-ethanoanthracene-11,12-di-carboxylic anhydride (3) through [4 + 2]-cycladdition between anthracene and maleic anhydride in refluxing xylene which was then condensed with para-aminophenol to give compound 5. Compounds 5 and 8 were characterized by their physical, elemental, and spectroscopic data. 2D-NMR (COSY, HSQC, and HMBC) techniques were used to confirm the structure of compound 5. Compounds 5 (MIC = 32–128 μg/mL) and 8 (MIC = 16–256 μg/mL) along with the precursor 3 (MIC = 64–128 μg/mL) displayed moderate to low antimicrobial activities against selected bacterial and fungal species when compared with those of nystatin (MIC = 0.50–2 μg/mL) and ciprofloxacin (MIC = 0.50–16 μg/mL) used as reference drugs.

Key words: Pyrrolidine, N-arylsuccinimid, Dibenzobarrelene, Phenols, Azo compound, Anti-microbial activities
Introduction

Pyrrolidines, also known as azolidines, are the simplest compounds in the azolidine group. They are cyclic amines with four carbon atoms having the general formula C₄H₉N. Pyrrolidine derivatives known as succinimid are cyclic imides with five vertices (Scheme 1) [1]; the simplest compound of this family is the succinimid of formula C₄H₅NO₂. The substitution of the nitrogen proton with aromatic groups yields N-arylsuccinimid type compounds. Pyrrolidines and their derivatives are essential structural units of many important compounds useful in the pharmaceutical field because they possess biological functions such as antimicrobial [2, 3], antitumor [4], anticonvulsant [5], antitubercular [6], and analgesic activities [7].

Synthetic compounds containing azo moieties have been found to possess biological functions similar in some cases to those of N-arylsuccinimid (e.g. antimicrobial [8, 9], antiinflammation [10], antioxidant [11]). In addition to these two groups biologically active compounds of synthetic origin, many natural occurring compounds such as phenols and polyphenols are biologically active. They are being extensively studied in various models and some their activities include antioxidants but also anti-tumor, antiinflammatory and antimicrobial [12–14].

Antibiotics have been widely used in the past decade to treat a variety of infectious diseases that remain one of the leading causes of mortality and morbidity in the world. Nevertheless, the massive use of these antibiotics has led to the emergence of pathogens multi resistant to conventional antibiotics [15]. Such resistant pathogens include the case of methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus; which sets the limits of the therapeutic treatments currently used [16]. One of the possible ways to fight this phenomenon is the development of new molecules. Previous work on pyrrolidine derivatives and azo compounds show that these compounds are very important because of their multiple biological activities [17–22]. Furthermore, Mkpenie and co-workers [23] recently found that the azo moiety (–N≡N–) was a pharmacophore responsible for activities in azo compounds. The motivation of this work is that to the best of our knowledge, azo compounds having the nucleus of dibenzobarrelene (Scheme 2) [24] have hitherto not been reported in the literature.
Furthermore, in contrary to pyrolidines, phenols and azo compounds, very few is known about the biological activity of dibenzobarrelene derivatives. Despite the individual biological function of N-arylsuccinimid, azo compounds and phenol molecules, synthesis strategies to incorporate them into a single molecule may be advantageous. That's why we combined in this work in a single molecular architecture the pyrrolidine-2,5-dione, phenol, fragment of dibenzobarrelene and the azo bridge, with the expectation to obtain a hybrid molecule with improved biological potentials.

Results and discussion
Chemistry
The preparation of compound 5 was done by the following procedure: A Diels–Alder reaction between anthracene 1 and maleic anhydride 2 leads to compound 3 which was subsequently condensed with para-aminophenol 4 in acetic acid at reflux to give the desired compound 5 with yield of 92% (scheme 3).

UV–visible spectrum shows that this compound 5 absorbs between 200 and 400 nm, the near UV range. This spectrum has several absorption bands: \( \lambda_{1\text{max}} = 250 \text{ nm} \), \( \lambda_{2\text{max}} = 355 \text{ nm} \), \( \lambda_{3\text{max}} = 395 \text{ nm} \) corresponding respectively to the electronic transitions \( \pi-\pi^* \) of chromophores C=C of benzene present in the base of dibenzobarrelene, of C=O and C=C of benzene present in succinimid. The high value of \( \lambda_{3\text{max}} \) is explained by the presence of auxochrome OH on benzene.

Its IR spectrum shows a characteristic broad absorption band around 3363 cm\(^{-1}\) attributable to the OH function of phenol. At 2973 cm\(^{-1}\) can also be observed a band corresponding to the valence C–H bonds of the benzene ring; the absorption band at 1696 cm\(^{-1}\) is attributable to the carbonyls (C=O) of the amides. Those at 1600 cm\(^{-1}\) and 1562 cm\(^{-1}\) are attributable to the valence bonds C=C of the aromatic cycle. The C–N and C–O functions are characterized by the presence of the bands at 1273 cm\(^{-1}\) and at 1202 cm\(^{-1}\) respectively.

Its mass spectrum shows two peaks of pseudo molecular ions, one at 390 (100%) corresponding to [M + Na]\(^+\) and the other at 757 (90%) corresponding to [2 M + Na]\(^+\) from which the molar mass of the compound was deduced to be m/z: 367 corresponding to the raw formula C\(_{24}\)H\(_{17}\)NO\(_3\).

Its \(^1\)H NMR spectrum shows, despite the symmetry, that the aromatic protons in dibenzobarrelene moiety are not equivalent due to the molecular arrangements [25]; so they have different signals. The doublet split at 7.32 (dd, 2H, J = 5.3 and 3.3 Hz) is assigned to the protons H-3, H-7 while that at 7.23 (dd, 2H, J = 5.4 and 3.3 Hz) is assigned to the protons H-2, H-6. The multiplet at 7.11 is attributed to the protons H-1, H-4, H-5, H-8. In the phenolic moiety, we have an AA'BB' proton system. The doublet at 6.62 (d, 2H, J = 8.8 Hz) is assigned to the proton H-2', H-6' and that at 6.17 (d, 2H, J = 8.8 Hz) is assigned to the protons H-3', H-5'. The low values of the chemical shifts of these benzenic protons are due to the mesomeric effect on the one hand of the OH group which shields in ortho position the protons H-3', H-5' and on the other hand the mesomeric effect of the nitrogen contained in the pyrrolidine cycle which also ortho shields the protons H-2', H-6'. The mesomeric effect of OH is greater than that of nitrogen, hence the strong shielding of the H-3', H-5' protons compared to those of H-2', H-6'. The singlet at 4.75 (s, 2H) is assigned to the benzylic protons H-9, H-10 and the other benzylic protons H-11, H-15 gives a singlet at 3.25 (s, 2H). The benzylic protons H-9, H-10, H-11, H-15 was expected to give doublets, but rather give
singlets due to the presence of a more electronegative phenyl group adjacent to each proton [25]. The COSY spectrum of this compound shows squares of correlation between the protons H-3 and H-4, H-2 and H-1, H-2' and H-3', H-9 and H-11. The $^{13}$C NMR spectrum of compound 5 has thirteen signals instead of twenty-four as in the molecular formula which confirm that there is symmetry in the molecule. Five signals are observed corresponding to quaternary carbons at 177.9 (C=O), 157.4 (C–OH), 141.2 (C=C), 138.8 (C=C) and 122.7 (C–N). There are also six signals attributable to protonated benzenic carbons at 127.6, 127.1, 126.8, 125.1, 124.3, 115.9 and two signals attributable to benzylic carbons at 46.9 and 45.8. The data of the spectra of this compound are in agreement with those found in the literature [26].

The synthesis of the azo compound was done in a two-step process including the diazotization of aniline (6) to form the diazonium ion 7 which then copulates with compound 5 to give the azo compound 8 with yield of 67% (Scheme 4).

The UV–visible spectrum of 8 showed a large band around $\lambda_{\text{max}}=385$ nm corresponding to the electronic absorption of the chromophores of the system contain azo group. There is also an extension of the peak and an increase in the absorbance of this compound to more than 1.5 compared to that of the compound 5; moreover, the conjugation of the C=C chromophores of arylsuccinimide and aniline by the azo bridge –N=N– promotes the absorption of this compound beyond 400 nm, in the visible region. In its IR spectrum, characteristic absorption bands for phenol and $\equiv$C–H of the benzene ring are present at 3367 and 3060 cm$^{-1}$, respectively. The absorption bands at 1768 cm$^{-1}$ and at 1696 cm$^{-1}$ are attributable to the carbonyls (C=O); the higher frequency band is allocated to symmetrical vibrations and the lowest frequency band is allocated to asymmetrical vibrations. The band at 1598 cm$^{-1}$ is attributable to the valence bonds C=C of the aromatic cycle. The azo function (–N=N–) is confirmed by the presence of an absorption band at 1465 cm$^{-1}$. The C–N and C–O functions are characterized by the presence of the bands at 1274 cm$^{-1}$ and at 1202 cm$^{-1}$ respectively. The absorption at 764 cm$^{-1}$ is attributable to the deformation of (C–H) aromatic.

On its mass spectrum in ESI$^+$ mode, we observed the pseudo molecular ions at 494 (100%) corresponding to [M + Na]$^+$ from which the molar mass of the compound was deduced to be m/z: 471 corresponding to the gross formula C$_{30}$H$_{21}$N$_3$O$_3$ (Scheme 5). The mass spectrum of compound 8 also contained fragments ions at 454 (20%) [M$^+$-OH], 394 (24%) [M$^+$-C$_6$H$_5$], 377 (18%) [M$^+$-OH-C$_6$H$_5$], 311 (11%) [M$^+$-OH-C$_6$H$_5$-CO$_2$-C-N$_2$+H$_2$O], 278 (15%) [M$^+$-OH-C$_{14}$H$_{10}$].

On the $^1$H NMR spectrum of compound 8, the protons of the aniline moiety H-2", H-3", H-4", H-5" and H-6" were exhibited at 7.45 (m, 5H) overlapping with the protons of the dibenzobarrelene nucleus. It’s also exhibited as in compound 5 the aromatic protons of the dibenzobarrelene moiety respectively at 7.40 (dd, 2H, $J=5.3$ and 3.2 Hz), 7.32 (dd, 2H, $J=5.3$ and 3.3 Hz), 7.19 (m, 4H). The benzylic protons appeared at 4.75 (s, 2H) and 3.25 (s, 2H). The phenolic moiety presents three types of protons, two doublets and a singlet. The singlet at 6.98 (s, 1H) is attributable to the proton H-6" whereas, the doublets at 6.68 (d, 1H, $J=8.1$ Hz) and 6.18 (d, 1H, $J=8.2$ Hz) are respectively
attributed to the protons H-2′ and H-3′. The $^{13}$C NMR of this compound showed more than sixteen carbons instead of thirteen as in compound 5; confirming therefore the above suggested substitution pattern. In addition to all the carbons present in compound 5, there are new carbon signals at 160.7 attributable to the depleted carbon C-1′′ of aniline carrying the azo group; that at 130.8 attributable to carbon C-5′ of the phenolic fragment bearing the azo group. Furthermore, one can notice an overlapping of the signals due to carbons C-2′′, C-3′′, C-4′′, C-5′′, C-6′′ at 129.1.

**XDR analysis**

The spectra of the X-ray diffraction analysis of compounds 5 and 8 are different from each other (Fig. 1). A large number of intense bands or peaks is observed on the spectrum of compound 5, whereas on the spectrum of compound 8 the number of bands is reduced and the intensities of the latter are low. This suggests that succinimid 5 has a better crystal structure and is therefore more stable than the azo compound [27]. In addition, this stability of compound 5 suggests a better cohesion between atoms compare to the azo compound [27]. This weak cohesion of atoms in the azo compound may be due to presence of the azo bridge (–N=N–). The optimized 3D view of compound 8 is clearly presented in Fig. 2.
Biology
Antimicrobial activity
The antimicrobial activities were evaluated on seven species of microorganisms including bacteria and yeasts and the data are summarized in Table 1. It appears from the results of these analyses that the activity of the compounds varies according to the nature of the microorganisms. Compounds 3, 5, 8 showed moderate to low antimicrobial activities respectively with MICs = (64–128) µg/mL, (32–128) µg/mL and (16–64) µg/mL on bacteria and 128 µg/mL, (64–128) µg/mL, (64–256) µg/mL on yeasts. It is noted that the introduction of the phenol fragment into compound 3 induced an increase in the activity of compound 5 in particular on *Staphylococcus aureus*, *Candida tropicalis* PK233, *Cryptococcus neoformans* H99 and remains unchanged on the other microorganisms. Furthermore, the introduction of the azo function in compound 5 resulted into an increase of the activity of compound 8, in particular on *Staphylococcus aureus*, *Vibrio cholera* SG24, *Vibrio cholera* CO6. The yeasts have shown a low sensitivity with respect to the azo compound, thus showing that this compound has much better antibacterial than antifungal activity on these types of microorganisms.

All the compounds tested showed weak biological activities compared to the reference drugs. Bactericidal effects (MBC/CMI ≤ 4) were observed on *S. aureus*, *V. cholera* NB2 and *V. cholera* SG24 with compounds 8, 5 and 3 while fungicidal effect (MFC/CMI ≤ 4) was recorded on *C. neoformans* H99 with compounds 8 and 3 and on *C. tropicalis* PK233 with compound 3. Compounds 8, 5 and 3 showed bacteriostatic effect (MBC/CMI > 4) against *V. cholera* CO6 and fungistatic effect on *Candida albicans* ATCC10231. Compounds 8 and 5 displayed fungistatic effect (MFC/CMI > 4) on *C. tropicalis* PK233 while fungistatic effect was recorded on *C. neoformans* H99 with compound 3.

Table 1
Antimicrobial activity (MIC, MBC and MFC in µg/mL) of synthesized compounds as well as reference antimicrobial drugs

| Compounds | Inhibition parameters | *S. aureus* | *V. cholerae* NB2 | *V. cholerae* SG24 | *V. cholerae* CO6 | *C. albicans* ATCC10231 | *C. tropicalis* PK233 | *C. neoformans* H99 |
|-----------|-----------------------|-------------|-------------------|-------------------|-------------------|------------------------|----------------------|-------------------|
| 8         | MIC 16 64             | 32 64       | 256               | 128               | 64                 |
|           | MBC or MFC 32 128     | 64 > 256    | > 256             | > 256             | > 256              |
|           | MBC or MFC /MIC 2 2   | /           | /                 | /                 | /                  |
| 5         | MIC 32 64             | 64          | 128               | 64                |
|           | MBC or MFC 32 128     | 128 > 256   | > 256             | > 256             |
|           | MBC or MFC /MIC 2 2   | /           | /                 | /                 |
| 3         | MIC 64 64             | 64          | 128               | 128               |
|           | MBC or MFC 128 128    | 128 > 256   | > 256             | 256               |
|           | MBC or MFC /MIC 2 2   | /           | /                 | 2                  |
| Reference drugs* | MIC 0.50 16 | 8 16 | 2 | 0.50 1 |
|           | MBC or MFC 0.50 16    | 8 16        | 2 | 0.50 1 |
|           | MBC or MFC /MIC 1 1   | 1 1         | 1 | 1 1 |

/* not determined, MIC Minimum Inhibitory Concentration, MBC Minimum Bactericidal Concentration, MFC Minimum Fungicidal Concentration
*Nystatin for yeasts and ciprofloxacin for bacteria were tested together with compounds 3, 5 and 8
The variations in the susceptibilities observed between the microorganisms and the compounds tested would be due to the differences in genetic constitutions that exist between the different microbial strains tested [28].

**Cytotoxic activity**

The cytotoxic activity of azo compounds against red blood cells (RBCs) was investigated using Triton X-100 as a positive control. Interestingly, none of the tested compounds showed cytotoxic activity against RBCs at concentrations up to 256 μg/mL (results not shown). This finding supports the selective toxicity of the tested compounds towards the tested bacteria and fungi.

**Conclusion**

The results of biological tests showed that compounds 3, 5, 8 possess antimicrobial activities. Although being less active than the compound taken as a reference, the azo compound has better antibacterial activity than the other two compounds especially on Staphylococcus aureus, Vibrio cholera SG24 and Vibrio cholera CO6 strains. The antimicrobial screenings revealed that all the tested compounds 8, 9, and 3 have moderate to low antibacterial and antifungal activities. These results show that the azo function (N=N) is indeed a pharmacophore and would be responsible for the biological activity in the azo molecules.

**Materials and methods**

**Instrumental method**

All Melting points are corrected and were determined with a STUART SCIENTIFIC Melting Point Apparatus Model SMP3. The TLCs were carried out on Eastman Chromatogram Silica Gel Sheets (13,181; 6060) with fluorescent indicator. A mixture of hexane and ethyl acetate (1:2) was used as eluent and iodine was used as revelator for the chromatograms. The IR spectra were measured with a Fourier Transform Infrared spectrometer Brucker Alpha. The UV spectra were recorded with a JENWAY 6715 UV–Vis Spectrophotometer. Combustion analyses were carried out with a C, H, N, and S Euro EA from Hektach Company, their results were found to be in good agreement. 

**Synthesis of 9,10-dihydro-9,10-ethanoanthracene-11,12-dicarboxylic anhydride (3)**

4.92 g (27.76 mmol) of anthracene and 2.43 g (23.80 mmol) of maleic anhydride are refluxed for 40 min in 50 ml of xylene. The solution obtained is filtered hot and left to stand for about a day for gentle and gradual crystallization of the product. The latter is then filtered, dried and crystallized from xylene to give 6.30 g (83%) of white crystals; mp: 315 °C (Lit [25]: 261–262 °C from xylene).

**Synthesis of 13-(4-hydroxyphenyl)-9,10-dihydro-9,10-ethanoanthracene-12,14-dicarboximide (5)**

4 g (0.0145 mol) of 3 are dissolved in 50 ml of acetic acid while hot. Excess para-aminophenol (4 g, 0.0367 mol) previously dissolved in 30 ml of acetic acid is added and the mixture is heated under reflux for 3 h and then cooled to room temperature. The solution is filtered and washed with aqueous ethanol (50%) and dried to give 4.84 g of a gray-colored product 5; mp: 337 °C (Lit [29]: 334–335 °C from DMF), yield 92% (Lit [29]: 57%); ESI–MS: 390.11 (M+Na). UV–Vis: λ_{max} (DMSO): 250, 335, 355, 395 nm. IR (potassium bromide): 3363 cm–1 (OH), 2973 (CH), 1696 (C=O), 1600–1562 cm–1 (CArO), 1273 (C-N), 1202 (C-O), 764 (=CH2) cm–1. 1H NMR (CDCl3) δ 7.32 (dd, 2H, J = 5.3 and 3.3 Hz, H-3, H-7), 7.23 (dd, 2H, J = 5.4 and 3.3 Hz, H-2, H-6), 7.11 (m, 4H, H-1, H-4, H-5, H-8). 4.75 (s, 2H, H-9, H-10), 3.25 (s, 2H, H-11, H-15), 6.62 (d, 2H, J = 8.8 Hz, H-2', H-6'), 6.17 (d, 2H, J = 8.8 Hz, H-3', H-5'). 13C (1H)-NMR (CDCl3) δ 177.9 (C-12, C-14), 157.4 (C-4'), 141.2 (C-4a, C-8a), 138.8 (C-1a, C-5a), 122.7 (C-1'), 127.6 (C-3', C-5'), 127.1 (C-1, C-5), 126.8 (C-4, C-8), 125.1 (C-3, C-7), 124.3 (C-2, C-6), 115.9 (C-2', C-6'), 46.9 (C-11, C-15) and 45.8 (C-9, C-10).
Anal. Calcd. for C_{24}H_{17}NO_{3} (367.12): C, 78.56; H, 4.66; N, 8.68; found: C, 76.12; H, 4.68; N, 8.91.

**Synthesis of 13-(4-hydroxy-3-(phenyl)diazinyl)phenyl)-9,10-dihydro-9,10-ethanoanthracene-12,14–dicarboximide (8)**

**Preparation of diazonium salt solution** Dry sodium nitrite (1.38 g, 2 mmol) was slowly added over a period of 30 min to concentrated sulfuric acid (5 mL) with occasional stirring. The solution was cooled to 0–5 °C. 1 g (1.07 mmol) of aniline (6) was dissolved in DMSO (5 mL) and cooled to 0–5 °C. The nitrosyl sulfuric acid solution was added to the amine solution and the temperature was maintained to 0–5 °C.

**Procedure for the preparation of the coupling product** Compound 5 (0.367 g, 1 mmol) was dissolved in DMSO (5 mL) and then cooled in an ice-bath at 0–5 °C. The diazonium solution 7 previously prepared was added dropwise over 1 h before neutralizing the sulfuric acid present with a 10 ml sodium acetate (10%) solution. 50 mL of ice-cold water was then added and the solution was filtered off after 30 min and rinsed with iced water. After crystallization from ethanol. After crystallization from ethanol (98%), 315 mg of compound 8 was obtained as brown powder; mp: 271 °C, Yield 67%; ESI–MS: 494.22 (M+H)+; IR (potassium bromide): 3367 cm⁻¹ (OH), 3060 (CH), 1696 (C=O), 1598 (C₁₁=N₁₁), 1465 (-N=N-), 1274 (C=N), 1202 (C=O), 764 (C=N) cm⁻¹; ¹H NMR(CDCl₃) δ ppm: 7.45 (m, 5H, H-2″, H-3″, H-4″, H-5″, H-6″). 7.40 (dd, 2H, J = 5.3 and 3.2 Hz, H-3, H-7). 7.32 (dd, 2H, J = 5.3 and 3.3 Hz, H-2, H-6). 7.19 (m, 4H, H-1, H-4, H-5, H-8). 6.98 (s, 1H, H-6′). 6.68 (d, 1H, J = 8.1, H-2′). 6.18 (d, 1H, J = 8.2, H-3′). 4.75 (s, 2H, H-9, H-10). 3.25 (s, 2H, H-11, H-15). ¹³C NMR (CDCl₃) δ ppm: 176.5, 160.7, 152.8, 1465, 1274, 1202, 1106, 47.0 and 46.1. Anal. Calcd. for C_{30}H_{21}N₃O₃ (433.2): C, 78.35; H, 4.83; N, 3.91.

**Antimicrobial evaluation**

**Tested microorganisms**

The antimicrobial activity was performed against four bacterial and three fungal species. The selected microorganisms were one Gram-positive *Staphylococcus aureus* ATCC25923, three Gram-negative *Vibrio cholera* NB2, *V. cholera* SG24 and *V. cholera* CO6 and three yeast strains *Candida albicans* ATCC10231, *Candida tropicalis* PK233 and *Cryptococcus neoformans* H99. These microorganisms were taken from our laboratory collection. The fungal and bacterial strains were grown at 37 °C and maintained on Sabouraud Dextrose Agar (SDA, Conda, Madrid, Spain) and nutrient agar (NA, Conda) slants respectively.

**Determination of Minimum Inhibitory Concentration (MIC) and Minimum Microbicidal Concentration (MMC)**

The antibacterial and antifungal activity was evaluated by determining the MICs and MBCs as previously described [28]. MICs of synthesized compounds were determined by broth micro dilution. Each test sample was dissolved in dimethylsulfoxide (DMSO) to give a stock solution. This was serially diluted two-fold in Mueller–Hinton Broth (MHB) for bacteria and Sabouraud Dextrose Broth (SDB) for fungi to obtain concentration ranges of 512 to 0.25 µg/mL. Then, 100 µL of each sample concentration was added to respective wells (96-well micro plate) containing 90 µL of SDB/MHB and 10 µL of inoculum to give final concentration ranges of 256 to 0.125 µg/mL. The final concentrations of microbial suspensions were 2.5 × 10⁶ cells/mL for yeasts and 10⁸ CFU/mL for bacteria. Dilutions of nystatin (Sigma-Aldrich, Steinheim, Germany) and ciprofloxacin (Sigma-Aldrich, Steinheim, Germany) were used as positive controls for yeasts and bacteria respectively. Broth with 10 µL of DMSO was used as negative control. MICs were assessed visually and were taken as the lowest sample concentration at which there was no growth or virtually no growth. The lowest concentration that yielded no growth after the sub-culturing was considered as the MBCs or MFCs. All the tests were performed in triplicate [28].

**Cytotoxicity assay**

Whole blood (10 mL) from albino rats was collected by cardiac puncture in EDTA tubes. The study was conducted according to the institutional guidelines and approved by the Cameroon National Ethical Committee (Reg. No. FWA-IRB00001954) and in compliance with the ARRIVE guidelines. Erythrocytes were harvested by centrifugation at room temperature for 10 min at 1000 xg and were washed three times in PBS buffer [30]. The cytotoxicity was performed as previously described [30].

**Abbreviations**

UV: Ultra-violet; IR: Infra-red; FTIR: Fourier-transform infrared spectroscopy; HRMS: High resolution mass spectroscopy; ¹H NMR: Proton nuclear magnetic resonance; ¹³C NMR: Carbon nuclear magnetic resonance; µg: Microgram; °C: Degree centigrade; h: Hour; g: Gram; mg: Milligram; L: Liter; mL: Milliliter; µL: Microliter; MIC: Minimum Inhibitory Concentration; MMC: Minimum Microbicidal Concentration; DMSO: Dimethylsulfoxide.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13065-022-00801-5.

Additional file 1: Figure S1. UV Spectrum of compound 5. Figure S2. IR Spectrum of compound 5. Figure S3. Mass Spectrum of compound 5. Figure S4. H NMR of compound 5. Figure S5. COSY of compound 5. Figure S6. 13C NMR of compound 5. Figure S7. HSQC Spectrum of compound 5. Figure S8. HMBC Spectrum of compound 5. Figure S9. UV Spectrum of compound 8. Figure S10. IR Spectrum of compound 8. Figure S11. HRMS ESI-Positive mode of compound 8. Figure S12. Mass Spectrum fragmentation of compound 8. Figure S13. 1H NMR of compound 8. Figure S14. 13C NMR of compound 8. Table S1. ARRIVE Essential 10. Table S2. ARRIVE Recommended Set.

Acknowledgements

Emmanuel Sopbué Fondjo gratefully acknowledges the financial support from DAAD (grant no. 91691265). Additional financial supports for the work were obtained from the University of Dschang’s research grant committee and the Cameroonian Ministry of Higher Education special research allocation. They are also grateful to the German Academic Exchange Service (DAAD) for the financial support granted to the Yaoundé-Bielefeld Graduate School of Natural Products with Antiparasite and Antibacterial Activities (YaBiNaPA, project no. 57316173).

Authors’ contributions

ESF design the research topic, provided the reagents and supervised the chemistry experimental work as well as the compilation of the chemistry parts of the paper; ASN carried out the chemistry part of the experimental work in the lab, contributed to the exploitation of the data and the paper drafting; JOTD performed the antibacterial and antifungal assays and contributed the compilation of the biological parts of the paper; GD performed the powder diffraction XRD measurements, helped in the interpretation of the XRD data and contributed in reviewing the whole manuscript’s draft; PFWS performed the GC–MS measurements, helped in the interpretation of the spectra and contributed in reviewing the whole manuscript’s draft; BNL performed the LC–MS measurements, helped in the interpretation of the spectra and contributed in reviewing the whole manuscript’s draft; AT performed the NMR measurements, helped in the interpretation of the spectra and contributed in reviewing the whole manuscript’s draft; JRK supervised the biological screening experiments and contributed in reviewing the whole manuscript’s draft. All authors have given approval to the final version of the paper. All authors read and approved the final manuscript.

Funding

DAAD (Grant N° 91691265) for SFE and DAAD (YaBiNaPA, project no. 57316173) for BNL.

Availability of data and materials

All spectra for the compound characterization are provided as Additional file 1. Also, the raw data for all biological evaluations are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

All the procedures and protocols involving animals and their care were followed in conformity with the institutional guidelines and approved by the Cameroonian National Ethical Committee (Reg. No. FWA-IRB00001954) and in compliance with the ARRIVE guidelines.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Laboratory of Applied Synthetic Organic Chemistry, Department of Chemistry, Faculty of Science, University of Dschang, P.O. Box 67, Dschang, Republic of Cameroon. 2 Research Unit of Microbiology and Antimicrobial Substances, Department of Biochemistry, Faculty of Science, University of Dschang, P.O. Box 067, Dschang, Republic of Cameroon. 3 In Vitro Antireprogenics Chemistry, Christian-Albrechts-Universitaet zu Kiel, Max-Eyth-Straße 2, 24118 Kiel, Germany. 4 Higher Teacher’s Training College, University of Yaoundé I, P.O. Box 47, Yaoundé, Cameroon. 5 Polymer Chemistry Laboratory, Faculty of Live Sciences, Rhein-Waal University of Applied Sciences, Marie-Curie Straße 1, 47533 Kleve, Germany. 6 Department of Chemistry, Carleton University, 1125 Colonel By Drive, Ottawa K1S5B6, Canada.

Received: 8 February 2021 Accepted: 11 January 2022

Published online: 03 March 2022

References

1. Rajput SS, Patil MM. Succininimes: synthesis, reaction and biological activity. Int J Pharm Pharm Sci. 2014;6(1):8–14.
2. Sudhakar KB, Prabhasakar V, Ravindranath LK, Kumari MS, Latha J. Synthesis, characterization and biological evaluation of novel trisubstituted quinazoline 1,2,4-triazole derivatives bearing cis-substituted pyridine and sulfonamide moieties. Eur J Pharm Med Res. 2015;2:873–99.
3. Narayana MB, Sharma L, Madhavan V. Synthesis and antimicrobial activity of some novel pyridine derivatives. Int J Chem Tech Res. 2012;4:903–9.
4. Xun L, Yalin L, Wenfang X. Design, synthesis, and evaluation of novel galloyl pyridine derivatives as potential anti-tumor agents. Bioorg Med Chem. 2006;14:1287–93.
5. Konnet MJ, Crider AM, Magarian EO. Potential long-acting anticonvulsants; synthesis and activity of succininimes containing an alkylating group at the 2 position. J Med Chem. 1977;20(3):405–9.
6. Isaka M, Prathumpai W, WongsP, Tanticharoen M, Hirsutellone F, Hirsutellone F. A dimer of antitubercular alkaloids from the seed Fusinus trichoderma Species BCC 7579. Org Lett. 2006;8(13):2815–7.
7. Cormela R, Filho VC, Rosa PW, Pereira CI, Schlémper V, Nunes RJ. Synthesis of new succinimides and sulfonlated derivatives with analgesic action in mice. Pharm Sci. 1997;3:67–71.
8. Sharma S, Jasvir K, Sandeep K, Poonam S. Synthesis, antibacterial and antifungal activities of some anils azo containing pyrazole moiety. Indian J Chem. 2014;53B:227–37.
9. Tamokou JD, Sopbué FE, Prodipta S, Kuiate JR, Ngongang DA, Sondengam BL, Kumar BP. Antibacterial and cytotoxic activities and SAR of some azo compound containing thiophene backbone. Pharmaco logia. 2016;7:182–92.
10. Rani P, Srivastava VK, Kumar A. Synthesis and anti-inflammatory activity of heterocyclic indole derivatives. Eur J Med Chem. 2004;39:449–52.
11. Kriaba L, Aitsa S, Boudenea A, Maher RMB, Ghennaf N, Louans A. Synthesis, characterization and antioxidant activity studies of new azo-compounds. J Biochem Technol. 2019;10:85–90.
12. Proestos C, Bozaris IS, Nychas GJE, Komaitis M. Analysis of flavonoids and phenolic acids in Greek aromatic plants: investigation of their antioxidant capacity and antimicrobial activity. Food Chem. 2006;95:664–71.
13. Mahmoud L. Biological activity of Bep Polips in health and disease. Asian Pac J Cancer Prev. 2006;7:22–31.
14. Benavente GO, Castillo J, Lorente J, Oruto A, Del-Rio JA. Antioxidant activity of phenolics extracted from Olea europaea L. leaves. Food Chem. 2000;68:457–62.
15. Armstrong D, Neu H, Peterson LR, Tomasz A. The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990. Microb Drug Resist. 1995;1(1):1–4.
16. Amal SY. Synthesis of some new bisindole derivatives and their biological activity. Int J Org Chem. 2016;6:187–91.
17. Bellina F, Renzo R. Synthesis and biological activity of pyrrole, pyrrolidine and pyrididine derivatives with two aryl groups on adjacent positions. Tetrahedron. 2006;62:7213–56.
18. Sopbué FE, Tsemeugne J, Tamokou JDD, Ngongang DA, Kuiate JR, Sondengam BL. Synthesis and antimicrobial activities of some novel thiophene containing azo compounds. Heterocyclic Communication. 2013;19:253–9.
19. Jarrahpour AA, Motamedifar M, Pakshir K, Hadi N, Zarei M. Synthesis of novel azo Schiff bases and their antibacterial and antifungal activities. Molecules. 2004;9:815–24.

20. Rajv AS, Dipti KD. Synthesis and antimicrobial evaluation of novel azo compounds. World J Pharm Pharm Sci. 2016;5(9):1149–54.

21. Tonelli M, Vazzana I, Tasso B, Boido V, Sparatore F, Fermeglia M, Paneni SM, Posocco P, Pricl S, Colla PL, Ibbca C, Secci B, Colla G, Loddo R. Antiviral and cytotoxic activities of amino-arylazo compounds and aryltriazene derivatives. Bioorg Med Chem. 2009;17:4425–40.

22. Mkpenie VG, Ebong IBO, Obot B, Abasiekong B. Evaluation of the effect of azo group on the biological activity of 1-(4-methylphenylazo)-2-naphthol. E J Chemistry. 2008;5(3):431–4.

23. İrfan Ç, Süleyman S. Synthesis of novel aza-heterocyclic derivatives from diester and diacid chlorides having the dibenzobarrelene skeleton. Synth Commun. 2018. https://doi.org/10.1080/00397911.2018.1437449.

24. Kaier K, Wilson C, Chalkley M, Davey PG, Suetens C, Grundmann H, Kraker M, Schumacher M, Woikewitz M, Frank U. Health and economic impacts of antibiotic resistance in European hospitals outlook on the BURDEN project. Infection. 2008;36:492–4. https://doi.org/10.1007/s10685-008-7714-2.

25. Madhurambal G, Ramasamy P, Srivivasan PA, Mojumdar SC. Synthesis and characterization of a novel non-linear optical (NLO) material, endo-anthracene maleic anhydride-diels-alder adduct of anthracene. J Therm Anal Calorim. 2006;86(3):601–4. https://doi.org/10.1007/s10973-006-7714-2.

26. Arya S, Kumar S, Rani R, Kumar N, Roy P, Sondhi SM. Synthesis, anti-inflammatory, and cytotoxicity evaluation of 9,10-dihydroanthracene-9,10-α, β-succinimide and bis-succinimide derivatives. Med Chem Res. 2013;22:4278–85. https://doi.org/10.1007/s00044-012-0439-6.

27. Sopbué FE, Siévè AD, Tamokou JD, Ekom ES, Djeukoua DKS, Doungmo G, Walters EM, Traompno A, Simon FFW, Kuate JR. Room temperature synthesis and characterization of Novel Bi (III) complex with 2-amino-3-carbomethoxy-4, 5, 6, 7-tetrahydrobenzene [B] thiophene as potential antimicrobial agent. Acta Chim Slov. 2020;67:203–11.

28. Tamokou JD, Tala FM, Waibo KH, Kuate JR, Tane P. Antimicrobial activities of methanol extract and compounds from stem bark of Vismia rubescens. J Ethnopharmacol. 2009;124:571–5.

29. Weber E, Finge S, Csoregh I. Modular design of hosts involving a rigid succinimide framework and N-bonded lateral groups: crystalline inclusion properties and crystal structures of inclusion compounds with dioxane, MeOH, and DMF. J Org Chem. 1990;56:7281–8.

30. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother. 2000;44:1485–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions